Clinical Trial Detail

NCT ID	NCT03313778
Title	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	ModernaTX, Inc.
Indications	Advanced Solid Tumor bladder urothelial carcinoma colorectal cancer esophagus adenocarcinoma melanoma gastric adenocarcinoma endometrial cancer lung non-small cell carcinoma lung small cell carcinoma head and neck squamous cell carcinoma
Therapies	mRNA-4157 + Pembrolizumab mRNA-4157
Age Groups:	adult senior